Pfizer Inc

• Charles River's full-year metrics track toward the upper guidance range. • The company unveiled a multi-year financial framework extending through 2030. • The Create the Future program targets substantial cumulative cost savings.

• Twist partnered with Eli Lilly to integrate data into TuneLab. • Third-quarter results showed double-digit revenue growth and improved margins. • Annual revenue reached $376.57M alongside a net loss of $77.67M.

• FDA approved Eli Lilly's once-weekly basal insulin Onswik for type 2 diabetes. • Eli Lilly reported $65.18B annual revenue and $20.64B net profit. • Analysts rate the stock as Buy with an average price target of $1306.81.

• Moderna stock rose due to positive Phase 3 oncology trial results and upcoming congress presentations. • FDA approval of updated COVID-19 vaccines and capital-raising initiatives reinforced institutional financial confidence. • Moderna reported annual revenue of $1.94 billion and a net loss of $2.82 billion.

• Tempus AI experienced strong buying momentum and pronounced intraday price volatility. • CEO Eric Lefkofsky presented a compelling revenue growth outlook at conference. • The company reported an annual revenue of $1.27B and net profit of $-245.03M.

• Arrowhead shares dropped despite positive Phase 1/2a data for ARO-DIMER-PA due to profit-taking. • The company reported annual revenue of $829.45M with a net loss of $1.63M. • Technical indicators show a MACD sell signal and an RSI of 27.985.